个人简介

现为中国药理学会药物代谢动力学专业委员会副主任委员、中国药理学会数学药理学会理事、中国药学会应用药理专业委员会委员、国家药品监督管理局药品审评专家和江苏省药品审评专家、江苏省青蓝工程跨世纪省级学术带头人培养对象和江苏省“333”工程培养对象（第二层次）。2009年度入选江苏高等学校优秀科技创新团队带头人，享受国务院政府特殊津贴。为《中国药科大学学报》、《中国药师》、《中国临床药理学与治疗学》、《World Journal of Pharmacology》编委、《Planta Med》、《Acta Pharmacologica sinica》、《Biochemical Pharmacology》等学术期刊的审稿专家

研究领域

主要研究方向：研究方向：中药药物代谢动力学、疾病状态下药物代谢动力学、血脑屏障与药物转运、药物相互作用和创新药物的药代动力学研究以及生理药物代谢动力学模型。近年来致力于基于机制的药物代谢动力学模型与转化医学关系研究。

近期论文

1. Liu L, Liu XD*. Alterations in function and expression of ABC transporters at blood-brain barrier under diabetes and the clinical significances. Front Pharmacol. 2014 Dec 10; 5:273. 2. Zhang J, Zhang M, Sun B, Li Y, Xu P, Liu C, Liu L*, Liu X*. Hyperammonemia enhances the function and expression of P-glycoprotein and Mrp2 at the blood-brain barrier through NF-κB. J Neurochem. 2014 Dec; 131(6):791-802. 3. Xu D, Li F, Zhang M, Zhang J, Liu C, Hu MY, Zhong ZY, Jia LL, Wang DW, Wu J, Liu L*, Liu XD*. Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes. Acta Pharmacol Sin. 2014 Sep; 35(9): 1215-25. doi: 10.1038/aps.2014.39. 4. Liu C, Hu MY, Zhang M, Li F, Li J, Zhang J, Li Y, Guo HF, Xu P, Liu L*, Liu XD*. Association of GLP-1 secretion with anti-hyperlipidemic effect of ginsenosides in high-fat diet fed rats. Metabolism. 2014 Oct; 63(10): 1342-51. doi: 10.1016/j.metabol.2014.06.015. 5. Li J, Guo HF, Liu C, Zhong Z, Liu L*, Liu XD*. Prediction of Drug Disposition in Diabetic Patients by Means of a Physiologically Based Pharmacokinetic Model. Clin Pharmacokinet. 2015 Feb; 54(2):179-93. doi: 10.1007/s40262-014-0192-8. 6. Li F, Zhang M, Xu D, Liu C, Zhong ZY, Jia LL, Hu MY, Yang Y, Liu L*, Liu XD*. Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure. Acta Pharmacol Sin. 2014; 35(6): 792-805. 7. Li J, Wang X, Liu H, Guo H, Zhang M, Mei D, Liu C, He L, Liu L*, Liu X*. Impaired hepatic and intestinal ATP-binding cassette transporter G5/8 was associated with high exposure of β-sitosterol and the potential risks to blood-brain barrier integrity in diabetic rats. J Pharm Pharmacol. 2014; 66(3):428-36. 8. Hu N, Hu MY, Duan R, Liu C, Guo HF, Zhang M, Yu YL, Wang XT, Liu L*, Liu XD*. The increased levels of fatty acids contributed to induction of hepatic CYP3A4 activityinduced by diabetes. An in vitro evidence from HepG2 cell and Fa2N-4 cell lines. J Pharmacol Sci. 2014; 124(4):433-44. 9. Jia LL, Zhong ZY, Li F, Ling ZL, Chen Y, Zhao WM, Li Y, Jiang SW, Xu P, Yang Y, Hu MY, Liu L*, Liu XD*. The aggravation of clozapine-induced hepatotoxicity by glycyrrhetinic Acid in rats. J Pharmacol Sci. 2014;124(4):468-79. 10. Guo H, Liu C, Li J, Zhang M, Hu M, Xu P, Liu L*, Liu X*. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions. J Pharm Sci. 2013; 102(8): 2819-36. 11. Liu C, Zhang M, Hu MY, Guo HF, Li J, Yu YL, Jin S, Wang XT, Liu L*, Liu XD*. Increased glucagon-like peptide-1 secretion may be involved in antidiabetic effects of ginsenosides. J Endocrinol. 2013; 217(2):185-96. [IF: 4.058] 12. Yu Y, Wang X, Liu C, Yao D, Hu M, Li J, Hu N, Liu L*, Liu X*. Combined contributions of over-secreted glucagon-like peptide 1 and suppressed insulin secretion to hyperglycemia induced by gatifloxacin in rats. Toxicol Appl Pharmacol. 2013; 266(3): 375-84. 13. Li F, Wang D, Xu P, Wu J, Liu L, Liu X*. Identification of the metabolites of anti-inflammatory compound clematichinenoside AR in rat intestinal microflora. Biomed Chromatogr. 2013 Jul 12. doi: 10.1002/bmc.2991. 14. Yang Y, Chen Y, Zhong ZY, Zhang J, Li F, Jia LL, Liu L, Zhu X*, Liu XD*. Validated LC-MS/MS assay for quantitative determination of deoxypodophyllotoxin in rat plasma and its application in pharmacokinetic study. J Pharm Biomed Anal. 2014;88:410-5. 15. Wang J, Xia S, Xue W, Wang D, Sai Y, Liu L, Liu X*. A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human. Eur J Pharm Sci. 2013; 50(3-4):290-302. 16. Jin S, Wang XT, Liu L, Yao D, Liu C, Zhang M, Guo HF, Liu XD*. P-glycoprotein and multidrug resistance-associated protein 2 are oppositely altered in brain of rats with thioacetamide-induced acute liver failure. Liver Int. 2013; 33(2): 274-82. 17. Wang D, Li F, Li P, Zhang J, Liu L, Xu P, Zhou L, Liu X*. Validated LC-MS/MS assay for the quantitative determination of clematichinenoside AR in rat plasma and its application to a pharmacokinetic study. Biomed Chromatogr. 2012; 26(10):1282-5. 18. Liu HY, Liu L, Li J, Duan R, Hu N, Guo HF, Zhong ZY, Liu XD*. Combined contributions of impaired hepatic CYP2C11 and intestinal breast cancer resistance protein activities and expression to increased oral glibenclamide exposure in rats with streptozotocin-induced diabetes mellitus. Drug Metab Dispos. 2012; 40(6): 1104-1112.